Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting
OXFORD, England, May 9, 2022 /PRNewswire/ -- Enara Bio, a biotechnology company advancing novel T-cell receptor (TCR) directed immunotherapies against unconventional, shared, cancer-specific
Source: finanznachrichten.de